Anti‐HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B
Liver International · 2023
DOI: 10.1111/liv.15536 ↗Kurz gefasst
Leserbrief in der Zeitschrift Liver International, 2023. Verfasst von Chiuan-Bo Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
- Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
- Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
ORCID-Profile: Tung-Hung Su, Jia-Horng Kao
Zitieren
APA
Huang, C. B., Su, T. H., & Kao, J. H. (2023). Anti‐HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B. Liver International. https://doi.org/10.1111/liv.15536
Vancouver
Huang CB, Su TH, Kao JH. Anti‐HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B. Liver International. 2023. doi:10.1111/liv.15536
BibTeX
@article{Huang2023,
author = {Huang, Chiuan-Bo and Su, Tung-Hung and Kao, Jia-Horng},
title = {Anti‐HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B},
journal = {Liver International},
year = {2023},
doi = {10.1111/liv.15536}
}
EUVIMED